¾Æ½Ã¾ÆÅÂÆò¾çÀÇ °æÇÇ ¾à¹° Àü´Þ ½Ã½ºÅÛ : Áö¿ªº° ºÐ¼® - À¯Çüº°, ¿ëµµº°, À¯Åë ä³Îº° ¿¹Ãø(2030³â)
Asia Pacific Transdermal Drug Delivery System Market Forecast to 2030 - Regional Analysis - by Type, Application, and Distribution Channel
¾Æ½Ã¾ÆÅÂÆò¾çÀÇ °æÇÇ ¾à¹° Àü´Þ ½Ã½ºÅÛ ½ÃÀåÀº 2022³â 90¾ï 2,989¸¸ ´Þ·¯¿¡¼ 2030³â¿¡´Â 128¾ï 2,077¸¸ ´Þ·¯·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¿¹Ãø±â°£ µ¿¾È º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR)Àº 4.5%·Î ÃßÁ¤µË´Ï´Ù.
½º¸¶Æ® ÆÐÄ¡¿Í 3D ÀÎ¼â ÆÐÄ¡ÀÇ Áøº¸°¡ ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ °æÇÇ ¾à¹° Àü´Þ ½Ã½ºÅÛ ½ÃÀå¿¡ ¹ÚÂ÷¸¦ °¡ÇÑ´Ù.
°æÇÇ ¾à¹° Åõ¿© °æ·Î´Â ½Å±ÔÇϰí Áö¼ÓÀûÀÎ ¾à¹° Àü´ÞÀÇ ½Å·ÚÇÒ ¼öÀÖ´Â ¼ö´Ü Áß ÇϳªÀÔ´Ï´Ù. ÀÌ ºÎ¹®¿¡¼ Áß¿äÇÑ ¿¬±¸°¡ ÀÌ·ç¾îÁö°í, ÀÌ ÇüÅÂÀÇ ¾à¹°Àü´Þ¿¡ ´ëÇÑ ¿¬±¸ÀÚÀÇ °ü½ÉÀÌ ³ô¾ÆÁö°í Àֱ⠶§¹®¿¡ ÇâÈÄ, ¸¹Àº °æÇÇ ÆÐÄ¡°¡ ½ÃÀå¿¡ µîÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. °æÇÇ ÆÐÄ¡´Â ´ÏÄÚÆ¾, ÆæÅ¸´Ò, ´ÏÆ®·Î±Û¸®¼¼¸°, Ŭ·Î´Ïµò°ú °°Àº ¾à¹°À» Àü´ÞÇÏ°í ´Ù¾çÇÑ º´¸®¸¦ Ä¡·áÇÏ´Â µ¥ »ç¿ëµË´Ï´Ù. ÃÖ±Ù, ÀÌ·¯ÇÑ ÆÐÄ¡´Â ´Ù¾çÇÑ ¿ëµµ·Î »ý¹°ÇÐÀû Á¦Á¦¸¦ Àü´ÞÇϱâ À§ÇØ ¿¬±¸µÇ°í ÀÖ½À´Ï´Ù. ½º¸¶Æ® ÆÐÄ¡´Â ȯÀÚÀÇ »óŸ¦ ¸ð´ÏÅ͸µÇÏ°í ±×¿¡ µû¶ó ¾à¹°Àü´ÞÀ» Á¶Á¤ÇÏ´Â ¼¾¼ ¹× ±âŸ ±â¼úÀ» °®Ãß°í ÀÖ½À´Ï´Ù. 2023³â 1¿ù Swansea UniversityÀÇ ¼ö¼® °úÇÐÀÚµéÀº ¸¶ÀÌÅ©·Î´Ïµé ±â¼úÀ» ÀÌ¿ëÇÏ¿© ÆÄŲ½¼º´°ú ¾ËÃ÷ÇÏÀ̸Ӻ´°ú °°Àº ½Å°æÅðÇ༺ ÁúȯÀÇ ¿°Áõ¼º ¹ÙÀÌ¿À¸¶Ä¿¸¦ °ËÃâÇÏ´Â »õ·Î¿î ½º¸¶Æ® ÆÐÄ¡¸¦ °³¹ßÇß½À´Ï´Ù. ÀÌ ½º¸¶Æ® ÆÐÄ¡´Â ³·Àº ħ½ÀÀ¸·Î ÇǺΠÀ庮À» °üÅëÇϵµ·Ï ¼³°èµÈ ´Ù¼öÀÇ ¸¶ÀÌÅ©·Î ¹Ù´Ã·Î ±¸¼ºµÇ¸ç, ÀÌÈÄ ÀÓ»óÀûÀ¸·Î Áß¿äÇÑ ¹ÙÀÌ¿À¸¶Ä¿¸¦ ¸ð´ÏÅ͸µÇÕ´Ï´Ù. ÀÏ¹Ý Å¬¸®´ÐÀ̳ª Áý¿¡¼ÀÇ POC(Point of Care) Áø´ÜÀ» À§ÇØ ÀÚ±â Åõ¿©°¡ °¡´ÉÇÕ´Ï´Ù. ÀÌ Çõ½ÅÀûÀÎ Á¶»ç´Â ½Å°æ ÅðÇ༺ ÁúȯÀÇ Á¶±â ¹ß°ßÀ» Å©°Ô º¯È½Ãų ¼ö ÀÖ½À´Ï´Ù.
ÇǺΠ¿Ü¿ë 3D ÇÁ¸°ÆÃ Á¦Ç° : 2021³â 11¿ù¿¡ National Library of Medicine¿¡ °ÔÀçµÈ ¡¸From Personalized Dressings to Drug Delivery¡¹¿¡ ÀÇÇϸé, ÇǺΠǥ¸é¿¡ ÀûÇÕÇÏ´Â °³ÀÎÈµÈ 3D ÇÁ¸°ÆÃ ÆÐÄ¡´Â ¾Æ¼¼Æ¿Çí»çÆéƼµå 3(AHP - 3) ¹è´Þ¿¡ »ç¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. º» Á¶»ç¿¡¼´Â Æú¸®¿¡Æ¿·»±Û¸®Äݵð¾ÆÅ©¸±·¹ÀÌÆ®(PEGDA)¿Í ºñ´ÒÇǷѸ®µ·(VP)ÀÇ 2À¯ÇüÀÇ ¾×ü ´Ü·®Ã¼¸¦ ´Ù¸¥ ºñÀ²·Î »ç¿ëÇÏ¿© ÃÖÁ¾ ÁßÇÕüÀÇ ±â°èÀû °µµ, ÁßÇÕ ¼Óµµ, ÆØÀ± ¼Óµµ¸¦ °³¼±ÇÏ¿´½À´Ï´Ù. ¼öÁö¿¡ ´ëÇÑ ÃÖÀûÀÇ ¾à¹° ´ãÁö´Â AHP - 3°¡ Á¦Á¶ °øÁ¤À» ÅëÇØ ¾ÈÁ¤ÀûÀ̰í ÃÖÁ¾ ÁßÇÕüÀÇ ¹°¼º¿¡ ¿µÇâÀ» ¹ÌÄ¡Áö ¾ÊÀ½À» º¸¿©ÁÖ¾ú½À´Ï´Ù. 3D ½ºÄµ ¾È¸é ¸ðµ¨À» »ç¿ëÇÏ¿© °³ÀÎÈµÈ ÆÐÄ¡¸¦ ÄÄÇ»ÅÍ Áö¿ø ¼³°è ¼ÒÇÁÆ®¿þ¾î·Î ¼³°èÇÏ°í µðÁöÅÐ ±¤ °¡°ø 3D ÇÁ¸°Å͸¦ »ç¿ëÇÏ¿© ÃÖÀûÈ µÈ ¼öÁö·Î Á¦ÀÛÇß½À´Ï´Ù. Á¦Á¶µÈ °æÇÇ ÆÐÄ¡ÀÇ ½ÃÇè°ü³» Ư¼ºÈ´Â Àΰ£ÀÇ ½Ãü ÇǺο¡ ħÅõÇÏ´Â ´É·ÂÀ» ³ªÅ¸³»¸ç, ¾ÐÃàÀÌ ´õÇØµµ ¹«¼Õ»óÀ¸·Î ³²¾Æ ÀÖÀ½À» È®ÀÎÇÏ¿´½À´Ï´Ù.
µû¶ó¼ 3D ÇÁ¸°ÆÃ ±â¼ú°ú ½º¸¶Æ® ÆÐÄ¡ÀÇ Ã¤ÅÃÀº ÇâÈÄ ¸î ³âµ¿¾È °æÇÇ ¾à¹° Àü´Þ ½Ã½ºÅÛ ½ÃÀå¿¡ ±âȸ¸¦ Á¦°ø ÇÒ °¡´É¼ºÀÌ ³ô½À´Ï´Ù.
¾Æ½Ã¾ÆÅÂÆò¾çÀÇ °æÇÇ ¾à¹° Àü´Þ ½Ã½ºÅÛ ½ÃÀå °³¿ä
¾Æ½Ã¾ÆÅÂÆò¾çÀÇ °æÇÇ ¾à¹° Àü´Þ ½Ã½ºÅÛ ½ÃÀåÀº Áß±¹, ÀϺ», Àεµ, È£ÁÖ, Çѱ¹ ¹× ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾çÀÇÀ¸·Î ±¸ºÐµË´Ï´Ù. °í·ÉÈ Àα¸ Áõ°¡, ½ÉÇ÷°ü Áúȯ À¯º´·ü Áõ°¡, ºñħ½À ÀÇ·á±â±â¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡·Î Áß±¹, Àεµ, È£ÁÖ µî ±¹°¡¿¡¼ ½ÃÀåÀÇ ±Þ¼ºÀåÀÌ ¿¹»óµÇ°í ÀÖ½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ¿¡¼´Â Áß±¹ÀÌ °æÇÇ ¾à¹° Àü´Þ ½Ã½ºÅÛÀÇ ÃÖ´ë ½ÃÀåÀÔ´Ï´Ù. Áß±¹¿¡¼ÀÇ °æÇÇ ¾à¹° Àü´Þ ½Ã½ºÅÛ ½ÃÀåÀÇ ¼ºÀåÀº ÁÖ·Î ÀÌ ³ª¶ó¿¡¼ÀÇ ±â¼ú ¼ºÀå, ÅëÁõ °ü¸®¸¦ À§ÇÑ °æÇÇ ÆÐÄ¡ ¹× ¹Ý°íÇü Á¦Ç°À» °³¹ßÇÏ´Â ½ÃÀå ÁøÃâ±â¾÷ Áõ°¡ ¶§¹®ÀÔ´Ï´Ù.
¶ÇÇÑ Áö³ ¸î ³âµ¿¾È Áß±¹ ±â¾÷Àº °æÇÇ ¾à¹° Àü´Þ ½Ã½ºÅÛ ¾÷°è¿¡¼ »ç¾÷À» È®´ëÇϱâ À§ÇØ Á¦Ç° »ó½Ã ¹× ½ÂÀÎ, Àμö, Á¦ÈÞ ¹× ÇÕº´À» ½Ç½ÃÇß½À´Ï´Ù. ¿¹¸¦ µé¾î, 2022³â 1¿ù¿¡ Suzhou Reveda Medical Co., Ltd.(REVEDA)´Â Hybio Pharmaceutical Co., Ltd. ´Ïµé ºÎ¹®À¸·Î Á¦ÈÞÇÑ´Ù°í ¹ßÇ¥Çß½À´Ï´Ù. ÇÕÀÛȸ»çÀÇ 60%´Â REVEDA Medical, 40%´Â Hybio PharmaceuticalÀÌ ¼ÒÀ¯Çϰí ÀÖ½À´Ï´Ù. °Ô´Ù°¡ 2021³â 9¿ù ¿µ±¹ÀÇ ÀǾàǰ,ÀÇ·áÁ¦Ç°±ÔÁ¦Ã»Àº ¾ËÃ÷ÇÏÀ̸Ӻ´¿¡ µû¸¥ °æµµ¿¡¼ ÁߵÀÇ Ä¡¸ÅÀÇ Ä¡·á·Î¼ Luye Pharma GroupÀÇ Çõ½ÅÀûÀÎ Á¦Á¦ÀÎ ¸®¹Ù½ºÆ¼±×¹Î °æÇÇÈí¼öÇü ÆÐÄ¡(Rivastigmine) Multi - Day Transdermal Patch : ¸®¹Ù½ºÆ¼±×¹Î MD) ÆÇ¸Å ½ÂÀÎÀ» ½ÂÀÎÇß½À´Ï´Ù. ÀÌ¹Ì À¯·´ÀÇ¿¬ÇÕ(EU) ȸ¿ø±¹ÀÇ ¸î °³±¹ÀÌ µ¿Á¦ÀÇ ÆÇ¸Å ½ÂÀÎÀ» ÃëµæÇϰí ÀÖ½À´Ï´Ù. ÀÌ¿Í °°ÀÌ À§ÀÇ ¿äÀÎÀ¸·ÎºÎÅÍ ÀÌ ³ª¶óÀÇ °æÇÇÈí¼öÇü ¾à¹° Àü´Þ½Ã½ºÅÛ ½ÃÀåÀº ÇâÈÄ ¼ö³â°£ ¼ö¿ä¸¦ ²ø¾î¿Ã¸± °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¾Æ½Ã¾ÆÅÂÆò¾çÀÇ °æÇÇ ¾à¹° Àü´Þ ½Ã½ºÅÛ ½ÃÀå ¼öÀͰú ¿¹Ãø(-2030³â)(±Ý¾×)
¾Æ½Ã¾ÆÅÂÆò¾çÀÇ °æÇÇ ¾à¹° Àü´Þ ½Ã½ºÅÛ ½ÃÀå ¼¼ºÐÈ
¾Æ½Ã¾ÆÅÂÆò¾çÀÇ °æÇÇ ¾à¹° Àü´Þ ½Ã½ºÅÛ ½ÃÀåÀº À¯Çü, ¿ëµµ, À¯Åë ä³Î, ±¹°¡·Î ±¸ºÐµË´Ï´Ù.
À¯Çüº°·Î ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ °æÇÇ ¾à¹° Àü´Þ ½Ã½ºÅÛ ½ÃÀåÀº °æÇÇ ÆÐÄ¡, °æÇÇ Á©, °æÇÇ ½ºÇÁ·¹ÀÌ µîÀ¸·Î ±¸ºÐµË´Ï´Ù. 2022³â ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ °æÇÇ ¾à¹° Àü´Þ ½Ã½ºÅÛ ½ÃÀå¿¡¼´Â °æÇÇ °Ö ºÎ¹®ÀÌ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÕ´Ï´Ù. °æÇÇ ÆÐÄ¡´Â ¶ÇÇÑ ¾à¹° Á¢Âø ÆÐÄ¡, ¸ÅÆ®¸¯½º ÆÐÄ¡, ÀúÀå¼Ò ¸· ÆÐÄ¡, Áõ±â ÆÐÄ¡·Î ¼¼ºÐȵ˴ϴÙ.
¿ëµµº°·Î ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ °æÇÇ ¾à¹° Àü´Þ ½Ã½ºÅÛ ½ÃÀåÀº ½ÉÇ÷°ü Áúȯ, ÁßÃß ½Å°æ Àå¾Ö, ÅëÁõ °ü¸®, È£¸£¸ó ¿ëµµ ¹× ±âŸ ¿ëµµ·Î ºÐ·ùµË´Ï´Ù. ÅëÁõ °ü¸® ºÎ¹®Àº 2022³â ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ °æÇÇ ¾à¹° Àü´Þ ½Ã½ºÅÛ ½ÃÀå¿¡¼ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ÅëÁõ °ü¸®´Â ¶ÇÇÑ ¿ÀÇÇ¿ÀÀÌµå ¹× ºñ ¿ÀÇÇ¿ÀÀ̵å·Î ÇÏÀ§ ºÎ¹®ÈµË´Ï´Ù. È£¸£¸ó ¾ÖÇø®ÄÉÀ̼ÇÀº ¶ÇÇÑ °æÇÇ ¿¡½ºÆ®·Î°Õ ¹× ÇÁ·Î°Ô½ºÅ×·Ð Ä¡·á¿Í Å×½ºÅ佺Å×·Ð º¸ÃæÀ¸·Î ¼¼ºÐȵ˴ϴÙ.
À¯Åë ä³Îº°·Î ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ °æÇÇ ¾à¹° Àü´Þ ½Ã½ºÅÛ ½ÃÀåÀº º´¿ø ¾à±¹, ¼Ò¸Å ¾à±¹, ¿Â¶óÀÎ ¾à±¹ µîÀ¸·Î ±¸ºÐµË´Ï´Ù. 2022³â ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ °æÇÇ ¾à¹° Àü´Þ ½Ã½ºÅÛ ½ÃÀå¿¡¼´Â º´¿ø ¾à±¹ ºÎ¹®ÀÌ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÕ´Ï´Ù.
±¹°¡º°·Î º¼ ¶§ ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ °æÇÇ ¾à¹° Àü´Þ ½Ã½ºÅÛ ½ÃÀåÀº Áß±¹, ÀϺ», Àεµ, È£ÁÖ, Çѱ¹ ¹× ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾çÀÇÀ¸·Î ºÐ·ùµË´Ï´Ù. 2022³â ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ °æÇÇ ¾à¹° Àü´Þ ½Ã½ºÅÛ ½ÃÀåÀº Áß±¹ÀÌ µ¶Á¡Çϰí ÀÖ½À´Ï´Ù.
Boehringer Ingelheim International GmbH, GSK Plc, Hisamitsu Pharmaceutical Co Inc, Johnson & Johnson, Luye Pharma Group Ltd, Novartis AG, Viatris Inc´Â ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ °æÇÇ ¾à¹° Àü´Þ ½Ã½ºÅÛ ½ÃÀå¿¡¼ »ç¾÷À» Àü°³Çϰí ÀÖ´Â ´ë±â¾÷ÀÔ´Ï´Ù.
¸ñÂ÷
Á¦1Àå ¼·Ð
Á¦2Àå ÁÖ¿ä ¿ä¾à
Á¦3Àå Á¶»ç ¹æ¹ý
- Á¶»ç ¹üÀ§
- 2Â÷ Á¶»ç
- 1Â÷ Á¶»ç
Á¦4Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ °æÇÇ ¾à¹° Àü´Þ ½Ã½ºÅÛ ½ÃÀå : ÁÖ¿ä »ê¾÷ ¿ªÇÐ
- ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
- ¸¸¼ºÁúȯÀÇ À¯º´·ü Áõ°¡
- ºñħ½À ¾à¹°Àü´Þ µð¹ÙÀ̽º¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡
- ¾àÁ¦ÀÇ ÀÚ±â Åõ¿©¿¡ ´ëÇÑ ³ôÀº ¼ö¿ä
- ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
- °æÇÇ ¾à¹° Àü´Þ ½Ã½ºÅÛÀÇ ºÎÀÛ¿ë°ú ¸®ÄÝ
- ½ÃÀå ±âȸ
- ½º¸¶Æ® ÆÐÄ¡¿Í 3D ÇÁ¸°ÆÃ ÆÐÄ¡ÀÇ Áøº¸
- ÇâÈÄÀÇ µ¿Çâ
- Á¦Á¶¾÷ü¿¡ ÀÇÇÑ Àü·«Àû ÀÌ´Ï¼ÅÆ¼ºê
- ¿µÇ⠺м®
Á¦5Àå °æÇÇ ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå : ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ½ÃÀå ºÐ¼®
- ¾Æ½Ã¾ÆÅÂÆò¾ç °æÇÇ ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå ¼öÀÍ ¿¹Ãø±â°£ µ¿¾È
Á¦6Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ °æÇÇ ¾à¹° Àü´Þ ½Ã½ºÅÛ ½ÃÀå : À¯Çüº° ¼öÀͰú ¿¹Ãø(-2030³â)
- ¼Ò°³
- ¾Æ½Ã¾ÆÅÂÆò¾ç °æÇÇ ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå(2022³â ¹× 2030³â) : À¯Çüº° ¸ÅÃâ¾× Á¡À¯À²(%)
- °æÇÇ ÆÐÄ¡
- °æÇÇ °Ö
- °æÇÇ ½ºÇÁ·¹ÀÌ
- ±âŸ
Á¦7Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ °æÇÇ ¾à¹° Àü´Þ ½Ã½ºÅÛ ½ÃÀå : ¿ëµµº° ¼öÀͰú ¿¹Ãø(-2030³â)
- ¼Ò°³
- ¾Æ½Ã¾ÆÅÂÆò¾ç °æÇÇ ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå(2022³â ¹× 2030³â) : ¿ëµµº° ¸ÅÃâ¾× Á¡À¯À²(%)
- ½ÉÇ÷°ü Áúȯ
- ÁßÃß ½Å°æ°è Áúȯ
- ÅëÁõ °ü¸®
- È£¸£¸ó ¿ëµµ
- ±âŸ
Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ °æÇÇ ¾à¹° Àü´Þ ½Ã½ºÅÛ ½ÃÀå : ¼öÀͰú ¿¹Ãø(-2030³â) À¯Åë ä³Îº°
- ¼Ò°³
- ¾Æ½Ã¾ÆÅÂÆò¾ç °æÇÇ ¾à¹° Àü´Þ ½Ã½ºÅÛ ½ÃÀå(2022³â ¹× 2030³â) : À¯Åë ä³Îº° ¸ÅÃâ Á¡À¯À²(%)
- º´¿ø ¾à±¹
- ¼Ò¸Å ¾à±¹
- ¿Â¶óÀÎ ¾à±¹
- ±âŸ
Á¦9Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ °æÇÇ ¾à¹° Àü´Þ ½Ã½ºÅÛ ½ÃÀå : ¼öÀͰú ¿¹Ãø(-2030³â) ±¹°¡º° ºÐ¼®
- Áß±¹
- ÀϺ»
- Àεµ
- È£ÁÖ
- Çѱ¹
- ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
Á¦10Àå °æÇÇ ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå ¾÷°è Á¤¼¼
- ¼Ò°³
- °æÇÇ ¾à¹° Àü´Þ ½Ã½ºÅÛ ½ÃÀåÀÇ ¼ºÀå Àü·«
- ¹«±âÀû ¼ºÀå Àü·«
- À¯±âÀû ¼ºÀå Àü·«
Á¦11Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ
- Novartis AG
- Johnson & Johnson
- GSK Plc
- Viatris Inc
- Boehringer Ingelheim International GmbH
- Hisamitsu Pharmaceutical Co Inc
- Luye Pharma Group Ltd
Á¦12Àå ºÎ·Ï
BJH
The Asia Pacific transdermal drug delivery system market is expected to grow from US$ 9,029.89 million in 2022 to US$ 12,820.77 million by 2030. It is estimated to register a CAGR of 4.5% from 2022 to 2030.
Advancements in Smart Patches and 3D-Printed Patches Fuel Asia Pacific Transdermal Drug Delivery System Market
A transdermal drug administration route is novel and one of the reliable means of sustained drug delivery. With significant research being conducted in this field and the increasing interest of researchers in this form of drug delivery, a large number of transdermal patches are likely to reach the marketplace in the future. Transdermal patches are used to deliver drugs such as nicotine, fentanyl, nitroglycerin, and clonidine to treat various medical conditions. Recently, these patches have been explored to deliver biologics in various applications. Smart patches are equipped with sensors and other technologies to monitor patient conditions and adjust drug delivery accordingly. In January 2023, a lead scientist at Swansea University developed a new smart patch to detect proinflammatory biomarkers of neurodegenerative diseases such as Parkinson's and Alzheimer's using the microneedle technology. These smart patches comprise numerous microneedles designed to penetrate the skin barrier in a minimally invasive manner, followed by monitoring the biomarkers of clinical significance. They can be self-administered for point-of-care diagnosis at general practices or at home. This innovative research can potentially change the landscape of early neurodegenerative disease detection.
According to an article titled "3D-Printed Products for Topical Skin Applications: From Personalized Dressings to Drug Delivery," published in the National Library of Medicine in November 2021, personalized 3D-printed patches that conform to the skin surface can be used for acetyl-hexapeptide 3 (AHP-3) delivery. In this study, two liquid monomers-polyethylene glycol diacrylate (PEGDA) and vinylpyrrolidone (VP)-were used in different proportions to improve the mechanical strength, polymerization rate, and swelling rate of the final polymer. Optimal drug loading on the resin indicated that AHP-3 remained stable throughout the manufacturing process and had no effect on the physical properties of the final polymer. Using a 3D scanned facial model, a personalized patch was designed in computer-aided design software, and it was fabricated in optimized resin using a digital light processing 3D printer. The in-vitro characterization of prepared transdermal patches has shown their ability to penetrate human cadaver skin, further remaining intact upon compression. "3D-Printed Products for Topical Skin Applications: From Personalized Dressings to Drug Delivery" is the first study demonstrating personalized patches made using photopolymers, and it has introduced a novel approach to improve the transdermal delivery of drugs for effective wrinkle management.
Thus, the adoption of 3D printing technology and smart patches is likely to offer opportunities to the transdermal drug delivery systems market in the coming years.
Asia Pacific Transdermal Drug Delivery System Market Overview
The Asia Pacific transdermal drug delivery systems market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. The market growth is expected to be fastest in countries such as China, India, and Australia due to growing aging population, increasing prevalence of cardiovascular diseases, and increasing demand for non-invasive medical devices. In Asia Pacific, China is the largest market of transdermal drug delivery systems. The growth of the transdermal drug delivery system market in China is primarily attributed to the growing technology in the country, increasing developments by the market players to develop transdermal patches and semisolid products for pain management.
Also, in the last few years, companies in China are undergoing product launches and approvals, acquisitions, partnerships, and mergers to expand their business in the transdermal drug delivery systems industry. For instance, in January 2022, Suzhou Reveda Medical Co., Ltd. (REVEDA) announced that it partnered with Hybio Pharmaceutical Co., Ltd. (Hybio Pharmaceutical) to set up a joint venture for drug-device combination products and team up in the field of polypeptide micro-needles for transdermal delivery. 60% of the joint venture will be owned by REVEDA Medical and 40% by Hybio Pharmaceutical. Furthermore, in September 2021, the UK's Medicines and Healthcare Products Regulatory Agency granted marketing approval for Luye Pharma Group's innovative formulation Rivastigmine Multi-Day Transdermal Patch (Rivastigmine MD) for the treatment of mild to moderate dementia associated with Alzheimer's disease. Several European Union nations already have marketing authorization for the medicine. Thus, owing to the abovementioned factors, the market is expected to propel the demand for transdermal drug delivery systems in this country in the upcoming years.
Asia Pacific Transdermal Drug Delivery System Market Revenue and Forecast to 2030 (US$ Million)
Asia Pacific Transdermal Drug Delivery System Market Segmentation
The Asia Pacific transdermal drug delivery system market is segmented into type, application, distribution channel, and country.
Based on type, the Asia Pacific transdermal drug delivery system market is segmented into transdermal patches, transdermal gel, transdermal sprays, and others. The transdermal gel segment held the largest share of the Asia Pacific transdermal drug delivery system market in 2022. The transdermal patches is further sub segmented into drug-in-adhesive patches, matrix patches, reservoir membrane patches, and vapor patches.
In terms of application, the Asia Pacific transdermal drug delivery system market is categorized into cardiovascular diseases, central nervous system disorders, pain management, hormonal applications, and other applications. The pain management segment held the largest share of the Asia Pacific transdermal drug delivery system market in 2022. The pain management is further sub segmented into opioid and non-opioid. The hormonal applications is further sub segmented into transdermal estrogen & progesterone therapy and testosterone replacement.
By distribution channel, the Asia Pacific transdermal drug delivery system market is segmented into hospitals pharmacies, retail pharmacies, online pharmacies, and others. The hospitals pharmacies segment held the largest share of the Asia Pacific transdermal drug delivery system market in 2022.
Based on country, the Asia Pacific transdermal drug delivery system market is categorized into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific transdermal drug delivery system market in 2022.
Boehringer Ingelheim International GmbH, GSK Plc, Hisamitsu Pharmaceutical Co Inc, Johnson & Johnson, Luye Pharma Group Ltd, Novartis AG, and Viatris Inc are some of the leading companies operating in the Asia Pacific transdermal drug delivery system market.
Table Of Contents
1. Introduction
- 1.1 The Insight Partners Research Report Guidance
- 1.2 Market Segmentation
2. Executive Summary
3. Research Methodology
- 3.1 Coverage
- 3.2 Secondary Research
- 3.3 Primary Research
4. Asia Pacific Transdermal Drug Delivery System Market - Key Industry Dynamics
- 4.1 Market Drivers
- 4.1.1 Increasing Prevalence of Chronic Diseases
- 4.1.2 Growing Demand for Noninvasive Drug Delivery Devices
- 4.1.3 High Demand for Self-Administration of Drugs
- 4.2 Market Restraints
- 4.2.1 Adverse Effects and Recall of Transdermal Drug Delivery Systems
- 4.3 Market Opportunities
- 4.3.1 Advancements in Smart Patches and 3D-Printed Patches
- 4.4 Future Trends
- 4.4.1 Strategic Initiatives by Manufacturers
- 4.5 Impact Analysis
5. Transdermal Drug Delivery System Market - Asia Pacific Market Analysis
- 5.1 Asia Pacific Transdermal Drug Delivery System Market Revenue (US$ Mn), 2022 - 2030
6. Asia Pacific Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 - by Type
- 6.1 Overview
- 6.2 Asia Pacific Transdermal Drug Delivery System Market Revenue Share, by Type 2022 & 2030 (%)
- 6.3 Transdermal Patches
- 6.3.1 Overview
- 6.3.2 Transdermal Patches: Asia Pacific Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
- 6.3.2.1 Drug-in-Adhesive Patches
- 6.3.2.1.1 Overview
- 6.3.2.1.2 Drug-in-Adhesive Patches: Asia Pacific Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
- 6.3.2.2 Matrix Patches
- 6.3.2.2.1 Overview
- 6.3.2.2.2 Matrix Patches: Asia Pacific Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
- 6.3.2.3 Reservoir Membrane Patches
- 6.3.2.3.1 Overview
- 6.3.2.3.2 Reservoir Membrane Patches: Asia Pacific Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
- 6.3.2.4 Vapor Patches
- 6.3.2.4.1 Overview
- 6.3.2.4.2 Vapor Patches: Asia Pacific Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
- 6.4 Transdermal Gels
- 6.4.1 Overview
- 6.4.2 Transdermal Gels: Asia Pacific Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
- 6.5 Transdermal Sprays
- 6.5.1 Overview
- 6.5.2 Transdermal Sprays: Asia Pacific Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
- 6.6 Others
- 6.6.1 Overview
- 6.6.2 Others: Asia Pacific Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
7. Asia Pacific Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 - by Application
- 7.1 Overview
- 7.2 Asia Pacific Transdermal Drug Delivery System Market Revenue Share, by Application 2022 & 2030 (%)
- 7.3 Cardiovascular Diseases
- 7.3.1 Overview
- 7.3.2 Cardiovascular Diseases: Asia Pacific Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
- 7.4 Central Nervous System Disorders
- 7.4.1 Overview
- 7.4.2 Central Nervous System Disorders: Asia Pacific Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
- 7.5 Pain Management
- 7.5.1 Overview
- 7.5.2 Pain Management: Asia Pacific Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
- 7.5.2.1 Opioid
- 7.5.2.1.1 Overview
- 7.5.2.1.2 Opioid: Asia Pacific Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
- 7.5.2.2 Non-Opioid
- 7.5.2.2.1 Overview
- 7.5.2.2.2 Non-Opioid: Asia Pacific Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
- 7.6 Hormonal Applications
- 7.6.1 Overview
- 7.6.2 Hormonal Applications: Asia Pacific Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
- 7.6.2.1 Transdermal Estrogen & Progesterone Therapy
- 7.6.2.1.1 Overview
- 7.6.2.1.2 Transdermal Estrogen & Progesterone Therapy: Asia Pacific Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
- 7.6.2.2 Testosterone Replacement
- 7.6.2.2.1 Overview
- 7.6.2.2.2 Testosterone Replacement: Asia Pacific Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
- 7.7 Other Application
- 7.7.1 Overview
- 7.7.2 Other Application: Asia Pacific Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
8. Asia Pacific Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 - by Distribution Channel
- 8.1 Overview
- 8.2 Asia Pacific Transdermal Drug Delivery System Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
- 8.3 Hospital Pharmacies
- 8.3.1 Overview
- 8.3.2 Hospital Pharmacies: Asia Pacific Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
- 8.4 Retail Pharmacies
- 8.4.1 Overview
- 8.4.2 Retail Pharmacies: Asia Pacific Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
- 8.5 Online Pharmacies
- 8.5.1 Overview
- 8.5.2 Online Pharmacies: Asia Pacific Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
- 8.6 Others
- 8.6.1 Overview
- 8.6.2 Others: Asia Pacific Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
9. Asia Pacific Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 - Country Analysis
- 9.1 Asia Pacific Transdermal Drug Delivery System Market
- 9.1.1 Asia Pacific Transdermal Drug Delivery System Market, by Country, 2022 & 2030 (%)
- 9.1.1.1 China: Asia Pacific Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
- 9.1.1.1.1 Overview
- 9.1.1.1.2 China: Asia Pacific Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
- 9.1.1.1.3 China: Asia Pacific Transdermal Drug Delivery System Market, by Type, 2020-2030 (US$ Million)
- 9.1.1.1.3.1 China: Asia Pacific Transdermal Drug Delivery System Market, For Transdermal Patches by Type, 2020-2030 (US$ Million)
- 9.1.1.1.4 China: Asia Pacific Transdermal Drug Delivery System Market, by Application, 2020-2030 (US$ Million)
- 9.1.1.1.4.1 China: Asia Pacific Transdermal Drug Delivery System Market, For Pain Management by Application, 2020-2030 (US$ Million)
- 9.1.1.1.4.2 China: Asia Pacific Transdermal Drug Delivery System Market, For Hormonal Applications by Application, 2020-2030 (US$ Million)
- 9.1.1.1.5 China: Asia Pacific Transdermal Drug Delivery System Market, by Distribution Channel, 2020-2030 (US$ Million)
- 9.1.1.2 Japan: Asia Pacific Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
- 9.1.1.2.1 Overview
- 9.1.1.2.2 Japan: Asia Pacific Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
- 9.1.1.2.3 Japan: Asia Pacific Transdermal Drug Delivery System Market, by Type, 2020-2030 (US$ Million)
- 9.1.1.2.3.1 Japan: Asia Pacific Transdermal Drug Delivery System Market, For Transdermal Patches by Type, 2020-2030 (US$ Million)
- 9.1.1.2.4 Japan: Asia Pacific Transdermal Drug Delivery System Market, by Application, 2020-2030 (US$ Million)
- 9.1.1.2.4.1 Japan: Asia Pacific Transdermal Drug Delivery System Market, For Pain Management by Application, 2020-2030 (US$ Million)
- 9.1.1.2.4.2 Japan: Asia Pacific Transdermal Drug Delivery System Market, For Hormonal Applications by Application, 2020-2030 (US$ Million)
- 9.1.1.2.5 Japan: Asia Pacific Transdermal Drug Delivery System Market, by Distribution Channel, 2020-2030 (US$ Million)
- 9.1.1.3 India: Asia Pacific Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
- 9.1.1.3.1 Overview
- 9.1.1.3.2 India: Asia Pacific Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
- 9.1.1.3.3 India: Asia Pacific Transdermal Drug Delivery System Market, by Type, 2020-2030 (US$ Million)
- 9.1.1.3.3.1 India: Asia Pacific Transdermal Drug Delivery System Market, For Transdermal Patches by Type, 2020-2030 (US$ Million)
- 9.1.1.3.4 India: Asia Pacific Transdermal Drug Delivery System Market, by Application, 2020-2030 (US$ Million)
- 9.1.1.3.4.1 India: Asia Pacific Transdermal Drug Delivery System Market, For Pain Management by Application, 2020-2030 (US$ Million)
- 9.1.1.3.4.2 India: Asia Pacific Transdermal Drug Delivery System Market, For Hormonal Applications by Application, 2020-2030 (US$ Million)
- 9.1.1.3.5 India: Asia Pacific Transdermal Drug Delivery System Market, by Distribution Channel, 2020-2030 (US$ Million)
- 9.1.1.4 Australia: Asia Pacific Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
- 9.1.1.4.1 Overview
- 9.1.1.4.2 Australia: Asia Pacific Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
- 9.1.1.4.3 Australia: Asia Pacific Transdermal Drug Delivery System Market, by Type, 2020-2030 (US$ Million)
- 9.1.1.4.3.1 Australia: Asia Pacific Transdermal Drug Delivery System Market, For Transdermal Patches by Type, 2020-2030 (US$ Million)
- 9.1.1.4.4 Australia: Asia Pacific Transdermal Drug Delivery System Market, by Application, 2020-2030 (US$ Million)
- 9.1.1.4.4.1 Australia: Asia Pacific Transdermal Drug Delivery System Market, For Pain Management by Application, 2020-2030 (US$ Million)
- 9.1.1.4.4.2 Australia: Asia Pacific Transdermal Drug Delivery System Market, For Hormonal Applications by Application, 2020-2030 (US$ Million)
- 9.1.1.4.5 Australia: Asia Pacific Transdermal Drug Delivery System Market, by Distribution Channel, 2020-2030 (US$ Million)
- 9.1.1.5 South Korea: Asia Pacific Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
- 9.1.1.5.1 Overview
- 9.1.1.5.2 South Korea: Asia Pacific Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
- 9.1.1.5.3 South Korea: Asia Pacific Transdermal Drug Delivery System Market, by Type, 2020-2030 (US$ Million)
- 9.1.1.5.3.1 South Korea: Asia Pacific Transdermal Drug Delivery System Market, For Transdermal Patches by Type, 2020-2030 (US$ Million)
- 9.1.1.5.4 South Korea: Asia Pacific Transdermal Drug Delivery System Market, by Application, 2020-2030 (US$ Million)
- 9.1.1.5.4.1 South Korea: Asia Pacific Transdermal Drug Delivery System Market, For Pain Management by Application, 2020-2030 (US$ Million)
- 9.1.1.5.4.2 South Korea: Asia Pacific Transdermal Drug Delivery System Market, For Hormonal Applications by Application, 2020-2030 (US$ Million)
- 9.1.1.5.5 South Korea: Asia Pacific Transdermal Drug Delivery System Market, by Distribution Channel, 2020-2030 (US$ Million)
- 9.1.1.6 Rest of Asia Pacific: Asia Pacific Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
- 9.1.1.6.1 Overview
- 9.1.1.6.2 Rest of Asia Pacific: Asia Pacific Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
- 9.1.1.6.3 Rest of Asia Pacific: Asia Pacific Transdermal Drug Delivery System Market, by Type, 2020-2030 (US$ Million)
- 9.1.1.6.3.1 Rest of Asia Pacific: Asia Pacific Transdermal Drug Delivery System Market, For Transdermal Patches by Type, 2020-2030 (US$ Million)
- 9.1.1.6.4 Rest of Asia Pacific: Asia Pacific Transdermal Drug Delivery System Market, by Application, 2020-2030 (US$ Million)
- 9.1.1.6.4.1 Rest of Asia Pacific: Asia Pacific Transdermal Drug Delivery System Market, For Pain Management by Application, 2020-2030 (US$ Million)
- 9.1.1.6.4.2 Rest of Asia Pacific: Asia Pacific Transdermal Drug Delivery System Market, For Hormonal Applications by Application, 2020-2030 (US$ Million)
- 9.1.1.6.5 Rest of Asia Pacific: Asia Pacific Transdermal Drug Delivery System Market, by Distribution Channel, 2020-2030 (US$ Million)
10. Transdermal Drug Delivery System Market Industry Landscape
- 10.1 Overview
- 10.2 Growth Strategies in the Transdermal Drug Delivery System Market
- 10.3 Inorganic Growth Strategies
- 10.4 Organic Growth Strategies
11. Company Profiles
- 11.1 Novartis AG
- 11.1.1 Key Facts
- 11.1.2 Business Description
- 11.1.3 Products and Services
- 11.1.4 Financial Overview
- 11.1.5 SWOT Analysis
- 11.1.6 Key Developments
- 11.2 Johnson & Johnson
- 11.2.1 Key Facts
- 11.2.2 Business Description
- 11.2.3 Products and Services
- 11.2.4 Financial Overview
- 11.2.5 SWOT Analysis
- 11.2.6 Key Developments
- 11.3 GSK Plc
- 11.3.1 Key Facts
- 11.3.2 Business Description
- 11.3.3 Products and Services
- 11.3.4 Financial Overview
- 11.3.5 SWOT Analysis
- 11.3.6 Key Developments
- 11.4 Viatris Inc
- 11.4.1 Key Facts
- 11.4.2 Business Description
- 11.4.3 Products and Services
- 11.4.4 Financial Overview
- 11.4.5 SWOT Analysis
- 11.4.6 Key Developments
- 11.5 Boehringer Ingelheim International GmbH
- 11.5.1 Key Facts
- 11.5.2 Business Description
- 11.5.3 Products and Services
- 11.5.4 Financial Overview
- 11.5.5 SWOT Analysis
- 11.5.6 Key Developments
- 11.6 Hisamitsu Pharmaceutical Co Inc
- 11.6.1 Key Facts
- 11.6.2 Business Description
- 11.6.3 Products and Services
- 11.6.4 Financial Overview
- 11.6.5 SWOT Analysis
- 11.6.6 Key Developments
- 11.7 Luye Pharma Group Ltd
- 11.7.1 Key Facts
- 11.7.2 Business Description
- 11.7.3 Products and Services
- 11.7.4 Financial Overview
- 11.7.5 SWOT Analysis
- 11.7.6 Key Developments
12. Appendix
- 12.1 About Us
- 12.2 Glossary of Terms